In areas where mother-to-infant spread of HBV is common, the first dose of vaccine should be given as soon as possible after birth(i.e. within 24 hours).
Australian scientists have found a potential cure for hepatitis B virus(HBV) infections, with a promising new treatment proving 100 per cent successful in eliminating the infection in preclinical models.
Unlike traditional vaccines, VLPs themselves are non-replicative because they do not carry any genetic material, and therefore are safe, having been used to make the FDA-approved vaccines for Hepatitis B virus and human papillomavirus.
In contrast, the price paid for getting immunity through natural infection might be mental retardation from Haemophilus influenzae type b(Hib), birth defects from rubella, liver cancer from hepatitis B virus, or death from measles.
Additionally, unlike traditional vaccines, virus like particles themselves are non-replicative, as described above, because they do not carry any genetic material, and therefore are safe, having been used to make the FDA-approved vaccines for Hepatitis B virus and human papillomavirus.
As many as 2.2 million persons in the United States are chronically infected with hepatitis B virus(HBV)(1), and approximately 15%- 25% of persons with chronic HBV infection will die prematurely from cirrhosis or liver cancer(2).
Since 1996, 29 outbreaks of hepatitis B virus(HBV) infection in long-term care facilities have been reported to the CDC, 25 of which involved adults with diabetes who were receiving assisted blood glucose monitoring.
Immunological research on the hepatitis B virus that aims to make a functional cure possible HBV is the causative virus of hepatitis B. Approximately 90% of patients with chronic hepatitis B caused by HBV infection experience no progression of the disease; only in 10% of cases does infection lead to cirrhosis or liver cancer.
Chronic infection of hepatitis B virus(HBV) and hepatitis C virus(HCV) and alcohol abuse are major causes of liver cirrhosis. Nowadays, we can suppress HBV viral proliferation by antiviral drugs, nucleotide/nucleoside analogues, to stop progress to liver cirrhosis.
B型肝炎ウイルス感染。
Hepatitis b virus infection.
B型肝炎ウイルスの治療や予防。
Treatment and prevention of hepatitis B virus.
B型肝炎ウイルスe抗体(HBeAb)。
Hepatitis B virus e antibody(HBeAb).
S5B型肝炎ウイルス感染のマネージメント。
S5 Infection control of hepatitis B virus.
B型肝炎ウイルス(HBV)はDNAウイルスである。
Hepatitis B virus(HBV) is a DNA virus..
B型肝炎ウイルスのみがDNAで、その他はRNAです。
Hepatitis B is the only DNA genome virus particle and all others are RNA only.
B型肝炎ウイルスの潜伏期間は30~180日です。
The incubation period for Hepatitis C is 30-180 days.
B型肝炎ウイルスキャリアは、「それは何を意味するのでしょうか?
Living with hepatitis B: What does it mean for you?
慢性B型肝炎ウイルス感染症-ニューヨーク市、2008年6月~2009年11月。
Surveillance for Chronic Hepatitis B Virus Infection- New York City, June 2008- November 2009.
HepetitisB演歌はB型肝炎ウイルス感染の治療や他の治療に適用されます。
Hepetitis B is used for Hepatitis b virus infection and other conditions.
あなたは体内のB型肝炎ウイルスの存在の一般的な症状を強調することができます。
General symptoms of the presence of hepatitis B virus can be distinguished.
English
中文
عربى
Български
বাংলা
Český
Dansk
Deutsch
Ελληνικά
Español
Suomi
Français
עִברִית
हिंदी
Hrvatski
Magyar
Bahasa indonesia
Italiano
Қазақ
한국어
മലയാളം
मराठी
Bahasa malay
Nederlands
Norsk
Polski
Português
Română
Русский
Slovenský
Slovenski
Српски
Svenska
தமிழ்
తెలుగు
ไทย
Tagalog
Turkce
Українська
اردو
Tiếng việt